The Complete Guide to CAR Design & Construction

CAR-T refers to Chimeric Antigen Receptor T-Cell Immunotherapy, which is a modification of the conventional T cell receptor TCR via a chimeric antigen receptor and is generally engineered into a monoclonal antibody antigen-binding domain. In the scFV segment, the modified CAR-T cells can specifically recognize tumor-associated antigens, and are not limited by MHC, so that the targeting, killing activity, and persistence of effector T cells are improved compared with conventional immune cells. CAR-T technology generally selects cytotoxic T lymphocytes (CTLs) for modification because CTLs recognize tumor antigens and release granzymes and perforin to kill tumors.